Fecal Transplant Therapy Market Report 2026

Fecal Transplant Therapy Market Overview

• Fecal Transplant Therapy market size has reached to $2.15 billion in 2025 • Expected to grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: Rising Inflammatory Bowel Disease (IBD) Prevalence Spurs Growth In Fecal Transplant Therapy • Market Trend: Advancements In Microbiota-Based Therapeutics And Their Impact On Fetal Transplant Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Fecal Transplant Therapy Market?

Fecal transplant therapy, also known as fecal microbiota transplantation (FMT), is a medical procedure that involves the transfer of stool (feces) from a healthy donor into the gastrointestinal (GI) tract of a recipient. This treatment primarily addresses recurrent Clostridium difficile infections and other gut-related issues. It aims to repopulate the patient’s gut with beneficial bacteria to improve their health and digestion. The main procedures of fecal transplant therapy are fecal enema, fecal bacteriotherapy, stool transplant, human probiotic infusion, and fecal transfusion. Fecal enema involves introducing stool from a healthy donor into a patient’s colon via an enema to restore gut flora balance. The various diseases include Clostridium difficile infection, autism, obesity, Parkinson's disease (PD), diabetes mellitus, and others. It has different end-users, such as hospitals, specialty clinics, and others.

What Is The Fecal Transplant Therapy Market Growth Forecast?

The fecal transplant therapy market size is expected to see strong growth in the next few years. It will grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing diversification of disease indications, rising demand for regulated and standardized products, expansion of outpatient fmt procedures, growing investment in microbiome therapeutics, advancements in automated stool processing systems. Major trends in the forecast period include increasing clinical adoption of stool-based therapies, rising development of capsule and suspension formats, growing exploration of neurological and metabolic indications, expansion of in-hospital fmt programs, enhanced emphasis on safety and standardization.

Global Fecal Transplant Therapy Market Segmentation

1) By Procedure: Fecal Enema, Fecal Bacteriotherapy, Stool Transplant, Human Probiotic Infusion, Fecal Transfusion 2) By Disease: Clostridium Difficile Infection, Autism, Obesity, Parkinson's Disease (PD), Diabetes Mellitus, Other Diseases 3) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Fecal Enema: Retention Enema, Cleansing Enema, Retention-Based Fecal Transplants, Home Administration Kits 2) By Fecal Bacteriotherapy: Suspension-Based Bacteriotherapy, Capsule Formulations, Customized Bacterial Preparations, Single Strain vs. Multi-Strain Products 3) By Stool Transplant: Direct Stool Transplant Procedures, Stool Suspension Transplant, Stool Capsule Transplant, Automated Stool Preparation Systems 4) By Human Probiotic Infusion: Single-Strain Probiotic Infusions, Multi-Strain Probiotic Infusions, Probiotic Blends With Prebiotics, Infusion Kits for Healthcare Providers 5) By Fecal Transfusion: Intravenous Fecal Transfusion, Transfusion via Gastrostomy Tube, Pre-Packaged Fecal Transfusion Solutions, Fecal Transfusion For Research Purposes

What Is The Driver Of The Fecal Transplant Therapy Market?

The increasing prevalence of inflammatory bowel disease is expected to propel the growth of fecal transplant therapy markets going forward. Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract, including conditions such as Crohn's disease and ulcerative colitis. The rise in inflammatory bowel disease cases is due to increased consumption of highly processed foods, frequent or inappropriate use of antibiotics, improved hygiene, and reduced exposure to infectious agents in childhood. Fecal transplant therapy aims to restore a healthy gut microbiota, which helps mitigate inflammation and improve symptoms in patients with inflammatory bowel disease, potentially influencing its management and progression. For instance, in June 2023, according to Crohn's and Colitis Canada, a Canada-based non-profit organization, there will be 470,000 inflammatory bowel disease (IBD) sufferers in Canada by 2035, up from an estimated 322,600 in 2023. Therefore, the increasing prevalence of inflammatory bowel disease is driving the growth of the fecal transplant therapy industry.

Key Players In The Global Fecal Transplant Therapy Market

Major companies operating in the fecal transplant therapy market are Mayo Clinic, Mount Sinai Health System Inc., Northwestern Medicine, NYU Langone Health, Michigan Medicine, UCLA Health, Duke University Health System Inc., Stanford Health Care, Ferring Pharmaceuticals, Cincinnati Children's Hospital Medical Center, Emory Healthcare, Cambridge University Hospitals NHS Foundation Trust, Hamilton Health Sciences Corporation, Brigham and Women's Faulkner Hospital Inc., Rebiotix Inc., Seres Therapeutics Inc., UPMC Hillman Cancer Center, OpenBiome, Center for Digestive Disease, BiomeBank Incorporated, The Regents of the University of California

Global Fecal Transplant Therapy Market Trends and Insights

Major companies operating in the fecal transplant therapy market are focused on developing innovative therapies, such as pill forms of fecal microbiota transplantation (FMT) therapy, to enhance patient compliance and broaden the therapy's accessibility. The pill form of fecal microbiota transplantation (FMT) therapy consists of encapsulated live bacteria from donor feces, designed to be taken orally. It aims to replenish healthy gut bacteria and improve intestinal health. For instance, in April 2023, Seres Therapeutics Inc., a US-based biotechnology company, and Nestlé Health Science S.A., a Switzerland-based healthcare company, launched VOWST. It is supplied as capsules, providing a convenient and less invasive treatment option to prevent recurrent clostridioides difficile infection (rCDI) in adults following antibacterial treatment. Unlike traditional fecal microbiota transplantation (FMT), which involves transferring whole stools, VOWST uses live bacterial spores of multiple Firmicute species derived from fecal microbiota from healthy human donors, believed to restore the gut microbiome.

What Are Latest Mergers And Acquisitions In The Fecal Transplant Therapy Market?

In September 2024, Metagen Therapeutics Inc., a Japan-based biotech startup, partnered with JSR Corporation to establish an investigational-drug manufacturing facility for microbiome medicines including oral fecal microbiota transplantation (FMT) drugs. With this partnership, Metagen Therapeutics and JSR aim to launch clinical trials of oral fecal-microbiota transplantation drugs, widen patient access to microbiome-based therapies, improve manufacturing and quality control, and accelerate development of treatments for conditions such as ulcerative colitis. JSR Corporation is a Japan-based materials and life-sciences company specializing in advanced materials innovation and biopharmaceutical manufacturing support.

Regional Outlook

North America was the largest region in the fecal transplant therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Fecal Transplant Therapy Market?

The fecal transplant therapy market includes revenues earned by entities through donor screening and selection, stool processing and preparation, and post-procedure monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Fecal Transplant Therapy Market Report 2026?

The fecal transplant therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the fecal transplant therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.